|Tested species reactivity||Human, Mouse, Non-human primate, Rat|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide surrounding Leu110 of human Akt1|
|Storage buffer||0.01M HEPES, pH 7.5, with 0.15M NaCl, 100µg/ml BSA, 50% glycerol|
|Contains||<0.02% sodium azide|
|Tested Applications||Dilution *|
|ChIP assay (ChIP)||1-3 ul|
|Immunohistochemistry (Paraffin) (IHC (P))||1:400|
|Western Blot (WB)||1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 1 publications below|
It is not recommended to aliquot this antibody.
This antibody is not cross-reactive with Akt2 or Akt3.
The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Multiple alternatively spliced transcript variants have been found for this gene.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect.
MA5-14898 was used in western blot to study the anti-tumor effects of a system for the GR-mediated delivery of anti-Hsp90 miRNA
|Pore SK,Choudhary A,Rathore B,Ganguly A,Sujitha P,Kumar CG,Agawane SB,Kumar JM,Scaria V,Pillai B,Banerjee R||Biomaterials (34:6804)||2013|